

# TARGET<sup>®</sup> Indiegene

Liquid

Speed Meets Precision, ctDNA Insights in just 5 Days.

Blood to Better Decisions—high-sensitivity comprehensive genomic profiling across 1,212 genes enabling precision therapy selection, resistance monitoring, and longitudinal disease assessment



# The **Indiegene Liquid** Advantage

1212 GENES. ONE BLOOD DRAW. MAXIMUM GENOMIC INSIGHTS.

## WHY TARGET INDIEGENE LIQUID?



### **Comprehensive ctDNA Profiling of 1212 genes in a Single Assay:**

Detects SNVs, Indels, CNAs, actionable fusions, MSI, and bTMB from a single blood sample



### **Actionable Fusion Detection Beyond Routine Liquid Biopsy:**

Includes high-priority targetable 11 DNA level fusions such as ALK, ROS1, RET, NTRK, FGFR, NRG, and MET exon 14 skipping.



### **Immunotherapy Biomarkers Included:**

Simultaneous assessment of both bTMB and MSI to support immunotherapy treatment decisions



### **Ideal When Tissue is Unavailable:**

Provides clinically meaningful genomic insights when tissue biopsy is insufficient, inaccessible, or unsuitable for repeat testing



### **Real-Time Tumor Evolution Tracking:**

Enables monitoring of treatment response, emerging resistance mechanisms, and disease progression through serial testing




### **Fast Clinical Decision Support:**

Delivers comprehensive ctDNA insights with a rapid 5-day turnaround time



### **Minimally Invasive Precision Oncology:**

Requires only a blood sample, reducing procedural risks and improving patient comfort







# Ideal Clinical Applications



PATIENTS WITH  
METASTATIC OR  
ADVANCED CANCERS

REAL-TIME MONITORING  
FOR PROGRESSION  
OR RESISTANCE

TISSUE-LIMITED OR  
INOPERABLE CASES



IMMUNOTHERAPY  
CONSIDERATION  
USING bTMB AND MSI

NON-INVASIVE  
SURVEILLANCE  
POST-TREATMENT

## Assay Specification and Performance Overview



### Gene Number

1212 Genes



### Sample Type

2x10 ml Blood in Streck Tubes



### Specificity and Sensitivity

99.99%



### Turn Around Time

5 working days



### Sequencing Chemistry

Hybrid Capture, End to End Sequencing  
of all the Exons of a given Gene



### Mean Sequencing Depth

15,000X

# Revolutionising Care, Personalising Hope Globally

With Precision Oncology, we're not just treating cancer.  
We're redefining what's possible in Cancer care.

Together, **We Beat** Cancer



● India   ● Nepal   ● Philippines   ● UAE



For any further information on 4baseCare Solutions and Services, please contact:

🌐 [4basecare.com](http://4basecare.com)   📞 +91 636-684-3415   ✉ [info@4basecare.com](mailto:info@4basecare.com)

📍 3rd floor, Summit B, Brigade Metropolis, Garudachar Palya, Bengaluru, Karnataka 560048